|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Isavuconazole (Cresemba), LC/MS/MS, Plasma*
Test Code13548
CPT Codes
80299<br>Restricted Client Code
Preferred Specimen
1 mL plasma submitted in a sterile, screw-cap vial
Minimum Volume
0.5 mL
Instructions
Collect 4-5 mL whole blood in EDTA tube (ACD and Sodium Heparin tubes are not acceptable).
Separate plasma by centrifugation within 30 minutes of draw time. Transfer 1 mL of plasma to a sterile, screw top tube. DO NOT draw in a gel tube.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Whole blood collected in serum or plasma gel tubes • Serum gel tubes • Specimen types other than those listed are not accepted
Methodology
LC/MS/MS
FDA Status
This test was developed and its performance characteristics determined by Eurofins Viracor. It has not been cleared or approved by the U.S. Food and Drug Administration.
Setup Schedule
Set up: Mon-Sat; Report available: 3 days
Reference Range
See Laboratory Report
Clinical Significance
Isavuconazole is for the treatment of life threatening fungal infections, specifically invasive aspergillosis and invasive mucormycosis.
1. There is a significant need for alternative antifungal therapies that address some of the limitations of voriconazole, such as reduced potential for nephrotoxicity for the intravenous formulation.
2. in addition to other dose-related toxicities.
3. Given the difficulty in diagnosis and similarity with which infections may present, having an antifungal that is effective for both indications would be particularly useful to physicians treating immunocompromised patients.
1. There is a significant need for alternative antifungal therapies that address some of the limitations of voriconazole, such as reduced potential for nephrotoxicity for the intravenous formulation.
2. in addition to other dose-related toxicities.
3. Given the difficulty in diagnosis and similarity with which infections may present, having an antifungal that is effective for both indications would be particularly useful to physicians treating immunocompromised patients.
